“We actively support the development, validation, use, and regulatory acceptance of non-animal testing methods to minimize the use of animal tests and are pleased to be one of the companies supporting this donation,” adds Dr. Maria Gogova, vice president of regulatory sciences at ALCS.
“We are pleased to be an industry partner in this important initiative. IIVS’ leadership in in vitro approaches should help to ensure the adoption of a non-animal testing paradigm for tobacco and nicotine products. We are witnessing remarkable advances in in vitro methodologies at present; these have several possible applications including much faster test results that are much more physiologically relevant to humans, ” says Dr. Marianna Gaca, head of pre-clinical assessment at BAT.
For all the latest news from PETA, visit peta.org.
